2023 could be a year of heightened biotech dealmaking activity
Shares of drugmakers Sanofi and Regeneron surged more than 6% on Mar 23 on COPD drug data.
Small-cap Immunocore has been a price leader within the biotech industry. Analysts have a "buy" rating on the stock and estimate that it will move 25% higher.
We highlight 4 ETFs that have started rebounding after a brutal sell-off
Pharma and biotech ETFs are in great shape and are trading at a one-month high level.
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and...
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and...
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and...
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and...
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and...